Tin tức & Cập nhật

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

Exposure to night-time road traffic noise (RTN) appears to adversely affect cardiovascular (CV) health, according to a study.

In an observational study of two community-based cohorts in Hong Kong, 6.7 percent of individuals with BMI ≥25 kg/m² were reclassified as nonobese after applying the Lancet Commission’s definition of obesity. Individuals with clinical obesity had the highest risk of adverse cardiovascular-kidney-metabolic (CKM) outcomes, while those reclassified as nonobese had an intermediate risk.